Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enalapril/folic acid or amlodipine/folic acid in type 2 diabetes with hypertension (observational, Shenzhen)
ChiCTR2200063451Phase 4Not yet recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enalapril, amlodipine and folic acid in essential hypertension, type 2 diabetes mellitus (T2DM) and hyperhomocysteinemia, sponsored by Shenzhen Second People's Hospital. Primary endpoints: Plasma homocysteine (Hcy) and Blood folate. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
enalaprilamlodipinefolic acid
03
Conditions
essential hypertensiontype 2 diabetes mellitus (T2DM)hyperhomocysteinemia
Beyond the preview
Go deeper on ChiCTR2200063451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063451.